DiaMedica Therapeutics Inc. (DMAC)
Stock Price:
$7.15 USD
0.24 (3.47%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
101.09M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-9.82M |
| Shares Out |
14.14M |
| EPS (ttm) |
-0.80 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$7.15 |
| Previous Close |
$6.91 |
| Change ($) |
0.24 |
| Change (%) |
3.47% |
| Day's Open |
6.92 |
| Day's Range |
6.76 - 7.34 |
| Day's Volume |
95,627 |
| 52-Week Range |
1.70 - 8.80 |
More Stats
| Market Cap |
101.09M |
| Enterprise Value |
88.41M |
| Earnings Date (est) |
Sep 1, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
14.14M |
| Float |
10.67M |
| EPS (basic) |
-0.81 |
| EPS (diluted) |
-0.80 |
| FCF / Share |
-0.68 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
19,633 |
| Short Ratio |
0.27 |
| Short % of Float |
0.15% |
| Beta |
2.16 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
7.28 |
| Revenue |
n/a |
| Operating Income |
-10.58M |
| Net Income |
-9.82M |
| Free Cash Flow |
-8.94M |
| Net Cash |
12.68M |
| Net Cash / Share |
0.90 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-44.28% |
| ROE |
-72.14% |
| ROIC |
-139.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$14.50*
(102.80% upside)
Low
14.0
Current: 7.15
High
15.0
Target: 14.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | 0.50 | - | - |
| Gross Profit | - | 0.50 | - | - |
| Operating Income | -11.59 | -6.76 | -4.52 | -2.33 |
| Net Income | -10.65 | -5.73 | -4.26 | -2.22 |
| Shares Outstanding | 11.99 | 7.74 | 5.94 | 4.74 |
| Earnings Per Share | -0.89 | -0.74 | -0.72 | -0.47 |
| Operating Cash Flow | -9.10 | -5.70 | -3.90 | -2.99 |
| Capital Expenditures | 0.01 | -0.05 | -0.02 | -0.01 |
| Free Cash Flow | -9.09 | -5.75 | -3.92 | -2.99 |
| Cash & Equivalents | 7.97 | 16.82 | 1.35 | 1.74 |
| Total Debt | 0.18 | 0.02 | - | - |
| Net Cash / Debt | 7.79 | 16.80 | 1.35 | 1.74 |
| Assets | 9.05 | 18.34 | 1.80 | 1.88 |
| Liabilities | 1.44 | 1.31 | 1.00 | 0.76 |
| Book Value | 7.62 | 17.03 | 0.80 | 1.11 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
DiaMedica Therapeutics Inc. |
| Country |
United States |
| Employees |
8 |
| CEO |
Rick John Pauls |
Stock Information
| Ticker Symbol |
DMAC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: DMAC |
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota.